Inspiremd Inc. · NASDAQ:NSPR
Inspiremd — Investor Presentation (January 2021)
25 slides from Inspiremd's investor presentation, Jan 19, 2021
Slide 1: emd.com/en,
emd.com/en, pit Jan. 15, 2021 www.ins, Q G i= ry &
Slide 2: Disclaimers
Disclaimers This presentation contains “forward-looking statements." Such statements may be preceded by the words “intends,” “may,” "will," “plans,” “expects,” “anticipates,” "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements ar
Slide 3: About InspireMD
™ About InspireMD InspireMD is a commercial-stage medical device company focused on stroke prevention in patients with carotid artery disease and treatment of other minimally : 4 MicroNet™ is a proprietary platform invasive indications utilizing an : i comprised of thin, 20-micron polyethylene . . °
Slide 4: Our Leadership
m™ Our Leadership Marvin L. Slosman President and CEO Craig Shore CFO Paul Stuka Chairman Michael Berman Director Campbell Rogers, M.D. Director Thomas Kester Director Gary Roubin, M.D., Ph.D. Director Mr. Slosman has over 30 years of experience in the medical device industry with focused leadership
Slide 5: InspireMD Pipeline
InspireMD Pipeline ducts Peripheral Treatment: PGuard™ EPS U Neuro Treatment: NGuard™ References: 1. Musialek P et al. PARADIGM-Extend Prospective Academic Trial: Accumulating long-term evidence for MicroNet-covered stent safety and stroke prevention efficacy. 5 Presentation at ESC Congress 2019, Pa
Slide 6: Endovascular Procedures: Landscape and InspireMD Potential
Endovascular Procedures: Landscape and InspireMD Potential CAD market CAROTID potential ARTERY open to DISEASE endo conversion 20% Endo® ww: |, 80% Surgical> 614K STILL procedures AWAITING in 2018 CONVERSION (estimated) 5 Already have been converted to endovascular procedures | Bekelis K, Gottlieb D
Slide 7: Stroke is the Second Biggest Cause of Death Globally
m™ Stroke is the Second Biggest Cause of Death Globally An estimated 15 million people suffer from stroke annually! *6.2 million deaths? Top Two Causes of Death Globally (2016)® * ~20% of all ischemic strokes are estimated to be oF caused by CAD (2.2-2.4 million)> Ischaemic Stroke Heart Disease +5 m
Slide 8: THE PROBLEM: Risks with Existing Approaches to CAD
m= THE PROBLEM: Risks with Existing Approaches to CAD Surgery (CEA) and conventional Carotid Artery Stenting (CAS) both come with risks Carotid Endarterectomy (CEA) Carotid Artery Stenting (CAS) Risk of complications: Risk of complications: ¢ Myocardial infarction risk’ (heart attack) * Procedural a
Slide 9: THE PROBLEM: Risk of Embolism Following Conventional CAS
THE PROBLEM: Risk of Embolism Following Conventional CAS 90% occlusion MRI of a pre-existing white Successful MRI reveals new multiple micro- of the carotid matter infarction opening of the infarcts (obstructions) due to artery (obstruction) carotid artery liberation of embolic particles Approximate
Slide 10: OUR SOLUTION: Proprietary MicroNet Technology
™ OUR SOLUTION: Proprietary MicroNet™ Technology New mesh covered stent that offers superior plaque coverage when compared to conventional stent approaches MicroNet™: an Embolic Prevention System (EPS) for Ultimate Thrombus Protection + Ultrathin flexible mesh sleeve, designed to expand seamlessly d
Slide 11: Mechanics Translate to Clinical Results
Mechanics Translate to Clinical Results 375u 1 10 ; ar Closed cell stent 2 * Average in lesion at expanded state inspire } Musialek, Piotr, MD DPHIL. Mesh-Covered Stents for Carotid Intervention: Rationale, Device Designs, Imaging and Data to Date . Presentation at TCT Congress 2015, San Francisco,
Slide 12: CGuard Shows Superiority Over Terumo RoadSaver at 1yr
m™ CGuard™ Shows Superiority Over Terumo RoadSaver at lyr META-ANALYSIS PUBLICATION UPDATE: Patient-level meta-analysis, 556 patients / 4 trials (both symptomatic and asymptomatic) iv | CGuard on track, demonstrating SUPERIORITY DUAL LAYER STENT 1 YEAR DATA (cumulative results according to Stent Pla
Slide 13: Carotid Solution: Our Well Studied Mesh-Covered Technology
™ Carotid Solution: Our Well Studied Mesh-Covered Technology More than 1,500 patients in Clinical Publications and Studies od Clinical Result the Carotid of the Embolic Preve Initial Clinical Resules and In Viero Testing. of the New CGuard MicroNet-Covered “One-Size-Fits-All” Carotid Stent _crtsun W
Slide 14: Timeline Growth: From Alternative Stent to New Gold Standard
Timeline Growth: From Alternative Stent to New Gold Standard YEAR STUDY PUBLICATION HIGHLIGHTS CGUARD'S STANDING (known & anticipated) Meta-Analysis CGuard superior to CEA at 1y-FU OCTOPVS OCT comparison CGuard vs CEA; CGuard superior post-intervention OCT than CEA O GGuard demonstrates OPTIMA IVUS
Slide 15: CGuard EPS Yields Superior Clinical Outcomes
m= CGuard™ EPS Yields Superior Clinical Outcomes When compared with Conventional Stents and Surgery (CEA), CGuard™ trends Superior 30 Day DSM (Death, Stroke, Myocardial Infarction) 6.00% 5.20% 5.00% 4.50% (0) 4.00% 3.00% > 00% 1.77% 0.8) 1.00% 0.00% CGuard™ Conventional Surgery Stents (CEA) 1, IRONG
Slide 16: A Billion Dollar Market Opportunity
= A Billion Dollar Market Opportunity Our MicroNet™-covered stents like CGuard™ could become the new gold standard WW carotid procedures today are Carotid procedures tomorrow could be primarily surgical: mostly minimally invasive with CGuard™ *2.2M diagnosed (and potentially as many as 13 million un
Slide 17: Commercial Footprint
m= Commercial Footprint (Dark Blue) ¢ Active Selling in 33 Countries ° Over 90% of sales are through channel partners / distributors ¢ Short Term Expansion Brazil and France ¢ New countries development include Japan, S Korea and China ¢ IDE approval in September 2020; targeting initiation of US tria
Slide 18: Growth Pathway to the U.S. Market
™ Growth Pathway to the U.S. Market *U .S. Market Opportunity* Size: 192K High Grade Carotid Artery Stenosis (HGCS) interventions in 2017 Opportunity : At a price of $1,650 per stent, the addressable market is estimated to be approximately $317 million = Executing on Approval of FDA PMA for U.S. Mar
Slide 19: Our Lead Product, CGuard - Advancing Rapidly
™ Our Lead Product, CGuard™ - Advancing Rapidly CGuard™ has potential (e) to become the new 3 1 fo) 2 0 1 0 0 0 + standard-of-care for carotid indications Total protected stents sold to date growth of CGuard™ milestones; *Achieved clinical So with excellent portfolio in Q4 elinicallresults neuroprot
Slide 20: Our Advancement Roadmap / Milestones
Our Advancement Roadmap / Milestones + Demonstrate Superiority of CGuard™ + Grow market share in those served + Launch CGuard™ jin Brazil + CGuard™ IDE Approval for U.S. + Advance Clinical Evidence + Expand share leadership CAS in EU + Growth in South American Markets + Initiate CGuard™ registration
Slide 21: Our Robust Intellectual Property Portfolio
m= Our Robust Intellectual Property Portfolio Proprietary platform technology supported by IP Patent Rights Issued Allowed Pending * InspireMD will continue to strengthen and broaden its patent protection globally to enable future pipeline products USA 14 1 3 Rest of World 38 0 3 inspireMD I 2
Slide 22: Our Business and Market Development
™ Our Business and Market Development Strategic Targets for Merger or Acquisition Synergy > > CSC“? > Gofmenafofaon Medtronic Cc) SERHc stryker NED prrered —TERUMO = Edwards COOK = ndlirenilieni& alos ons : — 5 “_ Weleriex: (BOMRID csi N ; NG - = a ChmicroPore ah nok 6h re «= SKROADD “Ojnarr @yteMai
Slide 23: The carotid space is seeing investment
™ The carotid space is seeing investment SILKROAD> Annual Revenue ($MM) A $80.0 First commercial case $70.0 ee October ee x 2015 $60.0 Pros $63.3} nae >) $50.0 wee . IPO; $600 million valuation $40.0 y $30.0 $34.6) ~ $20.0 eonpe ° $2 billion current valuation 2017 2018 2019 2020* * Annualized from Q
Slide 24: Summary Financials
m= Summary Financials NYSE AMERICAN NSPR Stock Price (1/13/21): $0.66 Average volume: 5.1M Shares outstanding (1/13/21): 61.7M Shares outstanding including full conversion of 648M preferred shares (1/12/21): , Market capitalization including full conversion of $42.8M preferred shares (1/12/21): , Ca
Slide 25: i=) s j= Qa. r) &
i=) s j= Qa. r) &